HEMOPTYSIS

Send This

Download

Comment

Favourite

more

Rating :

Rate It:

Embed :

Post a comment

Post Comment on Twitter Post Comment on SlideWorld

Comments:

Subscribe to follow-up comments

Notes

Hide Notes

Slide 1 :

HEMOPTYSIS DR.GOLMEI JD DNB TRAINEE NAZARETH HOSPITAL,SHILLONG. MODERATOR: DR.B BHUYAN. MD

Slide 2 :

HEMOPTYSIS Hemoptysis is defined as the expectoration of blood from the respiratory tract, a spectrum that varies from blood-streaking of sputum to coughing up large amounts of pure blood. The term massive hemoptysis is reserved for bleeding that is potentially life-threatening It has been defined by a number of different criteria, often ranging from more than 100 to more than 600 ml of blood over a 24 hour period

Slide 3 :

Classification: It has been variably classified in the literature based on : Appearance, Frequency, Rate , Volume, and potential for clinical consequences.

Slide 4 :

Epidemiology Depends on the underlying cause. In the United States, this is usually due to a viral or bacterial bronchitis. Worldwide, the most common cause of hemoptysis is tuberculous infection presumably owing to the high prevalence of the disease and its predilection for cavity formation.

Slide 5 :

Pathophysiology: Specific pathogenesis depends on etiology and location of disease. Due to inflammation/irritation of local respiratory tissue and its associated hyperplastic or otherwise abnormal vascular supply. Bronchial arterial circulation supplies high pressure blood to the airways and any associated pathology.

Slide 6 :

VASCULAR ORIGIN OF HEMOPTYSIS the most common site of hemoptysis is bleeding from the small- to medium-sized airways. Blood traversing the lungs can arrive from pulmonary arteries, or bronchial arteries Virtually the entire cardiac output courses through the low-pressure pulmonary arteries and arterioles en route to being oxygenated in the pulmonary capillary bed . In contrast, the bronchial arteries are under much higher systemic pressure but carry only a small portion of the cardiac output.

Slide 7 :

Slide 8 :

VASCULAR ORIGIN OF HEMOPTYSIS Despite the quantitatively smaller contribution of the bronchial circulation to pulmonary blood flow, the bronchial arteries are generally a more important source of hemoptysis than the pulmonary circulation In addition to being perfused at a higher pressure, they also supply blood to the airways and to lesions within the airways

Slide 9 :

DIFFERENTIAL DIAGNOSIS OF HEMOPTYSIS Before assuming a lower respiratory source of the bleeding, it is important to consider whether the blood may be coming from a non-pulmonary source, such as the upper airway or the gastrointestinal tract(ie.Pseudohemoptysis) Alkaline pH, foaminess, or the presence of pus may sometimes suggest the lungs as the primary source of bleeding rather than the stomach.

Slide 10 :

ETIOLOGY According to acuity: Acute or few episodes: bronchitis, pneumonia, trauma, PE, left heart failure. Subacute/recurrent : malignancy, cavitary lung disease(TB, Aspergilloma, lung abscess), AVM, pulmonary endometriosis. According to volume: Nonmassive hemoptysis : Bronchitis, malignancy, bronchiectasis, pneumonias

Slide 11 :

Massive hemoptysis : bronchiectasis, cavitary lung disease (TB, aspergiloma, lung abscess), AVM, malignancy. According to anatomic location: Airway: bronchitis/bronchiectasis, malignancy, foreign body, trauma. Parenchyma/alveoli: pneumonia, rheumatologic vasculitides and pulmonary hemorrhage syndromes( ANCA+Vasculitis. Goodpasture’s, SLE) Vascular: elevated pulmonary venous pressure ( LV Failure, mitral stenosis), PE, AVM, Varices/

Slide 12 :

Contd: Aneurysm, rheumatologic vasculitides and pulmonary hemorrhage syndromes. Coagulopathy: thrombocytopenia, DIC. Meds drugs: anticoagulants, aspirin, cocaine iatrogenic : lung biopsy, pulmonary arterial trauma (i.e., PA Catheter). Rare causes : Broncholithiasis, pulmonary endometriosis, bronchovascular fistula, bronchopulmonary sequestration. Idiopathic/undiagnosed upto 25% . pulmonary paragonimiasis

Slide 13 :

Airways diseases The most common source of hemoptysis is airways disease Inflammatory diseases, such as bronchitis or bronchiectasis Neoplasms, including primary bronchogenic carcinoma, endobronchial metastatic carcinoma or bronchial carcinoid In patients with AIDS, Kaposi's sarcoma involving the airways and/or the pulmonary parenchyma Foreign body & Airway trauma Fistula between a vessel and the tracheobronchial tree fistulas between the aorta and the airway are associated with aneurysms of the thoracic aorta and are fatal if not diagnosed and surgically treated Tracheo-innominate fistulas are a rare but potentially life-threatening complication of tracheostomy

Slide 14 :

Pulmonary parenchymal diseases Infection, especially tuberculosis, pneumonia, aspergilloma, and lung abscess Hemoptysis, which can be life-threatening, complicates the course of 50 to 85 percent of patients with an aspergilloma Tuberculosis can cause massive hemoptysis through multiple mechanisms Active cavitary or noncavitary lung disease can cause small or large amounts of bleeding Active disease can cause sudden rupture of a Rasmussen's aneurysm

Slide 15 :

Miscellaneous causes of pulmonary parenchymal hemorrhage Cocaine-induced pulmonary hemorrhage Hemoptysis has been described in six percent of habitual smokers of free-base cocaine ("crack") and has been associated with diffuse alveolar hemorrhage Catamenial hemoptysis hemoptysis that is recurrent and coincident with menses. The cause is intrathoracic endometriosis, usually involving the pulmonary parenchyma but occasionally affecting the airways

Slide 16 :

Pulmonary vascular disorders Pulmonary embolism Pulmonary AV malformation, either with or without underlying Osler-Weber-Rendu syndrome Elevated pulmonary capillary pressure mitral stenosis significant left ventricular failure Congenital heart disease severe pulmonary hypertension Iatrogenic pulmonary artery perforation from a Swan-Ganz catheter

Slide 17 :

Cryptogenic Depending upon the study, up to 30 percent of patients with hemoptysis have no cause identified even after careful evaluation In a series of 67 patients with cryptogenic hemoptysis, the prognosis was generally good, and most patients had resolution of bleeding within six months of evaluation Adelman, M, et al. Cryptogenic hemoptysis. Clinical features, bronchoscopic findings, and natural history in 67 patients. Ann Intern Med .

Slide 18 :

C/F Hemoptysis may be the only presenting sign or may accompany other manifestations of an underlying disorder.

Slide 19 :

Slide 20 :

EVALUATION OF HEMOPTYSIS The evaluation should begin with the initial history and physical examination supplemented by chest radiograph Important features of the history include age, smoking history, duration of hemoptysis, and association with symptoms of acute bronchitis or an acute exacerbation of chronic bronchitis

Slide 21 :

Important historical points to address Is there a history of prior lung, cardiac, or renal disease? Is there a history of cigarette smoking? Has the patient had prior hemoptysis, other pulmonary symptoms, or infectious symptoms? Is there a family history of hemoptysis or brain aneurysms (suggesting hereditary hemorrhagic telangiectasia)? Is there a history of skin rash? What is the patient's travel history? Does the patient have a history of asbestos exposure? Is there a history of bleeding disorders or use of aspirin, nonsteroidal anti-inflammatory drugs, or anticoagulants? Is there a history of upper airway or upper gastrointestinal complaints or diseases?

Slide 22 :

Physical examination The presence of many telangiectasias suggests HHT A skin rash may be suggestive of vasculitis Splinter hemorrhages suggest endocarditis or vasculitis Clubbing is nonspecific, since it can occur in many chronic lung diseases Pulmonary hypertension may be suggested by an augmented P2, murmurs of tricuspid regurgitation or pulmonic insufficiency, or a right ventricular lift Cardiac murmurs also raise the question of congenital heart disease, endocarditis with septic emboli, or, when a diastolic rumble or opening snap is present, mitral stenosis The legs should be examined carefully for possible deep venous thrombi

Slide 23 :

EVALUATION OF HEMOPTYSIS No immediate further work-up is indicated if the clinical picture is not suggestive of carcinoma negative chest radiograph, age less than 40 years, no smoking history, and hemoptysis less than 1 week duration but Is suggestive of acute bronchitis (blood streaking superimposed upon purulent sputum) Such a patient should be treated for bronchitis and observed for recurrence of hemoptysis following improvement in purulent sputum production

Slide 24 :

LABORATORY EVALUATION Additional studies which may be useful depending upon the particular clinical situation include hematocrit, urinalysis, blood urea nitrogen and plasma creatinine concentration, a coagulation profile, and collection of sputum for cytologic and microbiologic studies ABG if indicated. Immunologic disease: ANA/ANCA Screen, Anti-GBM antibodies, complement levels, Cryoglobulins etc. echocardiogram A transesophageal echocardiogram.

Slide 25 :

IMAGING PA/Lateral CXR should be performed in all cases of hemoptysis. Normal or nonlocalizing in upto 50% of all cases. Normal in up to 10% of cases caused by bronchogenic carcinoma.

Slide 26 :

EVALUATION OF HEMOPTYSIS Further evaluation is indicated if the patient has risk factors for carcinoma or if the hemoptysis does not occur in the setting of acute bronchitis Bronchoscopy is the preferred next procedure in those patients with risk factors for tumor or chronic bronchitis On the other hand, HRCT is the preferred next procedure in patients at lower risk for tumor or chronic bronchitis but with a history or radiograph suggestive of bronchiectasis or an arteriovenous malformation.

Slide 27 :

DIAGNOSTIC PROCEDURES Fiberoptic bronchoscopy often considered in patients with hemoptysis and a normal or nonlocalizing CXR to rule out endobronchial malignancy performed early in the evaluation, while the patient is actively bleeding, provides the highest yield for localizing the bleeding site Risk factors predicting those individuals most likely to have tumor found on bronchoscopy include Male sex Older age, greater than 50 years Smoking history greater than 40 pack years. Duration of hemoptysis greater than one week

Slide 28 :

Arteriography If the patient continues to bleed and the source is still unknown, then arteriography should next be performed, since it may be useful for therapy as well as diagnosis Since the majority of massive bleeds arise from the bronchial circulation, bronchial arteriography has a higher yield than arteriography of the pulmonary or systemic arterial beds When the pulmonary arterial circulation is the source, the most common underlying conditions are pulmonary AVM’s, Rasmussen's aneurysms or iatrogenic pulmonary artery tears

Slide 29 :

Computed tomography of the chest Use of early chest CT has been advocated to help localize the bleeding site and diagnose the cause of hemoptysis The advantage of CT is that it may suggest one of several diagnoses, such as bronchiectasis, lung abscess, and mass lesions, including cancer, mycetomas, and AVM’S It may also help in the acute setting to guide arteriography or bronchoscopy to the regions of highest yield The disadvantage of chest CT is that it may require temporary movement of an unstable patient away from intensive care

Slide 30 :

Fiberoptic bronchoscopy versus HRCT Fiberoptic bronchoscopy and HRCT are, in many ways, complementary studies, each with specific advantages in certain clinical situations In one study of 91 patients with hemoptysis, HRCT demonstrated all tumors seen by bronchoscopy as well as several which were beyond bronchoscopic range. On the other hand, HRCT could not detect bronchitis or subtle mucosal abnormalities which could be seen by bronchoscopy In another report of 57 patients, HRCT was particularly useful in diagnosing bronchiectasis and aspergillomas, while bronchoscopy was diagnostic of bronchitis and mucosal lesions such as Kaposi's sarcoma

Slide 31 :

ACUTE MANAGEMENT Initial priorities are insuring adequate airway protection, ventilation, and cardiovascular function Patients with poor gas exchange, rapid ongoing hemoptysis, hemodynamic instability, or severe shortness of breath should be orally intubated with a large bore endotracheal tube (size 8.0 or greater) Coagulation disorders should be rapidly reversed.

Slide 32 :

Slide 33 :

Slide 34 :

Protection of the nonbleeding lung If the location or side of bleeding is known, placing the bleeding lung in a dependent position may prevent blood spillage into the nonbleeding lung An alternative strategy involves placement of a typical, single lumen endotracheal tube into either the right or left mainstem bronchus The approach of selective intubation is less practical when the right lung is bleeding, because selective intubation of the left mainstem bronchus may be quite difficult A third alternative is the placement of a double lumen endotracheal tube specially designed for selective intubation of the right or left mainstem bronchi

Slide 35 :

Use of bronchoscopy in acute management A bronchoscopic option for protecting the non-bleeding lung is balloon tamponade of the bleeding site, involving placement of a Fogarty balloon catheter in the segmental or subsegmental bronchus leading to the bleeding site The balloon is left inflated for 24 to 48 hours, and the patient is then observed for rebleeding with the balloon deflated for several hours There is a potential risk of ischemic mucosal injury and postobstructive pneumonia, but these complications have not been reported

Slide 36 :

Use of bronchoscopy in acute management Bronchoscopic techniques used to slow or stop bleeding have included lavage with iced saline and application of topical epinephrine (1:20,000), vasopressin, thrombin, or a fibrinogen-thrombin combination None of these methods has been tested in controlled trials If bronchoscopy visualizes a localized bleeding mucosal lesion, laser therapy or electrocautery may be considered, if available

Slide 37 :

Arteriographic embolization The other option for the patient who continues to bleed is arteriographic embolization, either as "semi-definitive" treatment or as a bridge to elective surgery In the hands of experienced angiographers, embolization successfully stops bleeding more than 85 % of the time Unfortunately, embolization is only "semi-definitive," because rebleeding occurs in 10 to 20 percent of patients over the next 6 to 12 months Late rebleeding may be due to incomplete embolization, revascularization, or recanalization.

Slide 38 :

Medications: Factor VII Vasopressin Aminocaproic acid.

Slide 39 :

Surgery Patients with lateralized, uncontrollable bleeding should be assessed early for possible surgery Relative contraindications to surgery include severe underlying pulmonary disease, active TB, diffuse underlying lung disease (cystic fibrosis, multiple AVMs, multifocal bronchiectasis), and diffuse alveolar hemorrhage Morbidity and mortality are significantly greater with emergent surgery for persistent massive bleeding compared with elective surgery In most series of emergent therapy, surgical mortality for treatment of massive hemoptysis is approximately 20 %

Slide 40 :

Lobectomy/ pneumonectomy offers definitive cure. Indication: persistent focal/unilateral massive hemoptysis despite other therapy. Cavitary lung disease (i.e., aspergilloma) Localized bronchogenic ca. AVM , Traumatic injuries.

Slide 41 :

C/I : poor pulmonary reserve, Advanced malignancy , Active TB, Diffuse lung disease, Diffuse alveolar hemorrhage.

Slide 42 :

RECOMMENDATIONS First, stabilize the patient and then perform early bronchoscopy along with other appropriate diagnostic studies If the patient continues to bleed aggressively, arteriography is most reasonable for localization and therapy If bleeding persists despite embolization or if the patient is too ill to go to angiography, then blockade therapy or a double lumen tube should be considered While surgery remains the only truly definitive therapy, it should not be used in the acute emergent setting unless it cannot be avoided

Slide 43 :

Outcome/prognosis: Mortality depends on etiology and amount. Upto 80% with massive hemoptysis due to malignancy. Less than 10% with nonmassive hemoptysis. Less than 1% in bronchiectasis, lung infections.

Slide 44 :

Reference: Harrison’s principle of internal medicine 17th/18th edition. Washington manual of Medical therapeutics. Internet .

Slide 45 :

Thank you

Free Powerpoint Templates

	drgolmeijd2009 1 Years ago.



928 Views, 0 favourite
PowerPoint Presentation on HEMOPTYSIS
More By User Flag as inappropriate Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details. Cancel